AML1-ETO rapidly induces acute myeloblastic leukemia in cooperation with the Wilms tumor gene, WT1 - PubMed (original) (raw)
Comparative Study
. 2006 Apr 15;107(8):3303-12.
doi: 10.1182/blood-2005-04-1656. Epub 2005 Dec 27.
Naoki Hosen, Toshiaki Shirakata, Keisuke Kanato, Masashi Yanagihara, Shin-ichi Nakatsuka, Yoshihiko Hoshida, Tsutomu Nakazawa, Yukie Harada, Naoya Tatsumi, Akihiro Tsuboi, Manabu Kawakami, Yoshihiro Oka, Yusuke Oji, Katsuyuki Aozasa, Ichiro Kawase, Haruo Sugiyama
Affiliations
- PMID: 16380455
- DOI: 10.1182/blood-2005-04-1656
Free article
Comparative Study
AML1-ETO rapidly induces acute myeloblastic leukemia in cooperation with the Wilms tumor gene, WT1
Sumiyuki Nishida et al. Blood. 2006.
Free article
Abstract
AML1-ETO, a chimeric gene frequently detected in acute myelogenous leukemia (AML), inhibits the differentiation of myeloid progenitors by suppressing genes associated with myeloid differentiation and increases the replating ability of clonogenic myeloid progenitors. However, AML1-ETO alone cannot induce AML and thus additional genetic events are required for the onset of AML. The Wilms tumor gene (WT1), which has been identified as the gene responsible for Wilms tumor, is expressed at high levels in almost all human leukemias. In this study, we have generated transgenic mice (WT1-Tg) that overexpress WT1 in hematopoietic cells to investigate the effects of WT1 on AML1-ETO-associated leukemogenesis. AML1-ETO-transduced bone marrow (BM) cells from WT1-Tg mice exhibited inhibition of myeloid differentiation at more immature stages and higher in vitro colony-forming ability compared with AML1-ETO-transduced BM cells from wild-type mice. Most importantly, all of the mice that received a transplant of AML1-ETO-transduced BM cells from the WT1-Tg mice rapidly developed AML. These results demonstrate that AML1-ETO may exert its leukemogenic function in cooperation with the expression of WT1.
Similar articles
- Persistence of multipotent progenitors expressing AML1/ETO transcripts in long-term remission patients with t(8;21) acute myelogenous leukemia.
Miyamoto T, Nagafuji K, Akashi K, Harada M, Kyo T, Akashi T, Takenaka K, Mizuno S, Gondo H, Okamura T, Dohy H, Niho Y. Miyamoto T, et al. Blood. 1996 Jun 1;87(11):4789-96. Blood. 1996. PMID: 8639850 - KRAS (G12D) cooperates with AML1/ETO to initiate a mouse model mimicking human acute myeloid leukemia.
Zhao S, Zhang Y, Sha K, Tang Q, Yang X, Yu C, Liu Z, Sun W, Cai L, Xu C, Cui S. Zhao S, et al. Cell Physiol Biochem. 2014;33(1):78-87. doi: 10.1159/000356651. Epub 2014 Jan 17. Cell Physiol Biochem. 2014. PMID: 24480914 - AML1/ETO proteins control POU4F1/BRN3A expression and function in t(8;21) acute myeloid leukemia.
Dunne J, Gascoyne DM, Lister TA, Brady HJ, Heidenreich O, Young BD. Dunne J, et al. Cancer Res. 2010 May 15;70(10):3985-95. doi: 10.1158/0008-5472.CAN-09-3604. Epub 2010 May 11. Cancer Res. 2010. PMID: 20460523 Free PMC article. - AML1-ETO driven acute leukemia: insights into pathogenesis and potential therapeutic approaches.
Hatlen MA, Wang L, Nimer SD. Hatlen MA, et al. Front Med. 2012 Sep;6(3):248-62. doi: 10.1007/s11684-012-0206-6. Epub 2012 Aug 9. Front Med. 2012. PMID: 22875638 Review. - Acute myeloid leukemia with the 8q22;21q22 translocation: secondary mutational events and alternative t(8;21) transcripts.
Peterson LF, Boyapati A, Ahn EY, Biggs JR, Okumura AJ, Lo MC, Yan M, Zhang DE. Peterson LF, et al. Blood. 2007 Aug 1;110(3):799-805. doi: 10.1182/blood-2006-11-019265. Epub 2007 Apr 5. Blood. 2007. PMID: 17412887 Free PMC article. Review.
Cited by
- Dual intron-targeted CRISPR-Cas9-mediated disruption of the AML RUNX1-RUNX1T1 fusion gene effectively inhibits proliferation and decreases tumor volume in vitro and in vivo.
Neldeborg S, Soerensen JF, Møller CT, Bill M, Gao Z, Bak RO, Holm K, Sorensen B, Nyegaard M, Luo Y, Hokland P, Stougaard M, Ludvigsen M, Holm CK. Neldeborg S, et al. Leukemia. 2023 Sep;37(9):1792-1801. doi: 10.1038/s41375-023-01950-9. Epub 2023 Jul 18. Leukemia. 2023. PMID: 37464068 Free PMC article. - Understanding WT1 Alterations and Expression Profiles in Hematological Malignancies.
Niktoreh N, Weber L, Walter C, Karimifard M, Hoffmeister LM, Breiter H, Thivakaran A, Soldierer M, Drexler HG, Schaal H, Sendker S, Reinhardt D, Schneider M, Hanenberg H. Niktoreh N, et al. Cancers (Basel). 2023 Jul 4;15(13):3491. doi: 10.3390/cancers15133491. Cancers (Basel). 2023. PMID: 37444601 Free PMC article. - Evaluating Established Roles, Future Perspectives and Methodological Heterogeneity for Wilms' Tumor 1 (WT1) Antigen Detection in Adult Renal Cell Carcinoma, Using a Novel N-Terminus Targeted Antibody (Clone WT49).
Novacescu D, Cut TG, Cumpanas AA, Latcu SC, Bardan R, Ferician O, Secasan CC, Rusmir A, Raica M. Novacescu D, et al. Biomedicines. 2022 Apr 15;10(4):912. doi: 10.3390/biomedicines10040912. Biomedicines. 2022. PMID: 35453662 Free PMC article. - WT1 β'ing catenin into shape: a new interaction driving epigenetic plasticity in acute myeloid leukemia?
Grey W. Grey W. Haematologica. 2023 Jan 1;108(1):5-6. doi: 10.3324/haematol.2022.281119. Haematologica. 2023. PMID: 35443569 Free PMC article. No abstract available. - Crosstalk between β-catenin and WT1 signaling activity in acute myeloid leukemia.
Wagstaff M, Tsaponina O, Caalim G, Greenfield H, Milton-Harris L, Mancini EJ, Blair A, Heesom KJ, Tonks A, Darley RL, Roberts SG, Morgan RG. Wagstaff M, et al. Haematologica. 2023 Jan 1;108(1):283-289. doi: 10.3324/haematol.2021.280294. Haematologica. 2023. PMID: 35443562 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous